Ambulation Improves Frailty Scores in Patients With Multiple Myeloma
Resistance training and walking can be beneficial for patients with multiple myeloma.
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Findings from the PACIFIC-R trial showed that patients with EGFR-mutated non-small cell lung cancer experienced shorter progression-free survival with durvalumab than patients with EGFR-wildtype disease.
Olanzapine Significantly Reduces CINV in Patients Receiving MEC
Reimagining Frailty Screenings in Head and Neck Cancer
Screening for Pain and Depression is Not Enough in Cancer Care
Niraparib-Based Triplet Therapy Offers OS Advantage in BRCA1/2+ mCRPC